However, several studies have reported that high immunogenic cancer patients with B2M defect can still exhibit durable responses to anti-PD-1 therapy, suggesting the involvement of immune cell subsets beyond CD8+ T cells in these responses (70, 71). Here, CD8A is linked to cancer.